These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 16413352

  • 21. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS.
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [Abstract] [Full Text] [Related]

  • 22. Prevalence of osteoporosis, osteopenia, and vertebral fractures in long-term renal transplant recipients.
    Marcén R, Caballero C, Uriol O, Fernández A, Villafruela JJ, Pascual J, Martins J, Rodriguez N, Burgos FJ, Ortuño J.
    Transplant Proc; 2007 Sep; 39(7):2256-8. PubMed ID: 17889156
    [Abstract] [Full Text] [Related]

  • 23. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
    Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miwa S, Maeda Y, Kadono Y, Takashima M, Koh E, Namiki M.
    Urology; 2009 Jun; 73(6):1342-6. PubMed ID: 19371939
    [Abstract] [Full Text] [Related]

  • 24. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.
    Yaturu S, DjeDjos S, Alferos G, Deprisco C.
    Prostate Cancer Prostatic Dis; 2006 Jun; 9(1):35-8. PubMed ID: 16276350
    [Abstract] [Full Text] [Related]

  • 25. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus.
    Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED.
    Arthritis Rheum; 2007 Jun; 56(6):1966-73. PubMed ID: 17530722
    [Abstract] [Full Text] [Related]

  • 26. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS.
    Cancer; 2004 Aug 01; 101(3):541-9. PubMed ID: 15274067
    [Abstract] [Full Text] [Related]

  • 27. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Campbell SC, Bhoopalam N, Moritz TE, Pandya M, Iyer P, Vanveldhuizen P, Ellis NK, Thottapurathu L, Garewal H, Warren SR, Friedman N, Reda DJ.
    Urology; 2010 May 01; 75(5):1138-43. PubMed ID: 20303574
    [Abstract] [Full Text] [Related]

  • 28. Incidence and risk factors for low trauma fractures in men with prostate cancer.
    Ahlborg HG, Nguyen ND, Center JR, Eisman JA, Nguyen TV.
    Bone; 2008 Sep 01; 43(3):556-60. PubMed ID: 18585119
    [Abstract] [Full Text] [Related]

  • 29. Peripheral and central measurements of bone mineral density are equally strongly associated with clinical risk factors for osteoporosis.
    Patel R, Blake GM, Fogelman I.
    Calcif Tissue Int; 2007 Feb 01; 80(2):89-96. PubMed ID: 17308990
    [Abstract] [Full Text] [Related]

  • 30. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
    Morabito N, Gaudio A, Lasco A, Catalano A, Atteritano M, Trifiletti A, Anastasi G, Melloni D, Frisina N.
    J Bone Miner Res; 2004 Nov 01; 19(11):1766-70. PubMed ID: 15476575
    [Abstract] [Full Text] [Related]

  • 31. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.
    J Urol; 2006 May 01; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [Abstract] [Full Text] [Related]

  • 32. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.
    J Urol; 2003 Jun 01; 169(6):2008-12. PubMed ID: 12771706
    [Abstract] [Full Text] [Related]

  • 33. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R.
    BJU Int; 2008 Jul 01; 102(1):44-7. PubMed ID: 18336606
    [Abstract] [Full Text] [Related]

  • 34. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
    Higano CS.
    Nat Clin Pract Urol; 2008 Jan 01; 5(1):24-34. PubMed ID: 18185511
    [Abstract] [Full Text] [Related]

  • 35. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
    Spry NA, Galvão DA, Davies R, La Bianca S, Joseph D, Davidson A, Prince R.
    BJU Int; 2009 Sep 01; 104(6):806-12. PubMed ID: 19281463
    [Abstract] [Full Text] [Related]

  • 36. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.
    Int J Urol; 2007 Dec 01; 14(12):1071-5. PubMed ID: 18036042
    [Abstract] [Full Text] [Related]

  • 37. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.
    Bernat MM, Pasini J, Mareković Z.
    Coll Antropol; 2005 Dec 01; 29(2):589-91. PubMed ID: 16417166
    [Abstract] [Full Text] [Related]

  • 38. Progressive osteoporosis during androgen deprivation therapy for prostate cancer.
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT.
    J Urol; 2000 Jan 01; 163(1):181-6. PubMed ID: 10604342
    [Abstract] [Full Text] [Related]

  • 39. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ, Srinivas S, Perkash I, Terris MK.
    Urology; 2001 Jan 01; 57(1):127-32. PubMed ID: 11164157
    [Abstract] [Full Text] [Related]

  • 40. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
    Kawahara T, Kobayashi T, Nishizawa K, Kobori G, Mitsumori K, Ogura K.
    Hinyokika Kiyo; 2008 Apr 01; 54(4):261-6. PubMed ID: 18516917
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.